Clinical Trial Update: Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial of Selonsertib for nonalcoholic steatohepatitis (NASH) with bridging fibrosis (F3) was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Selonsertib (selonsertib)

Snippet

Sponsor: Gilead Sciences | Conditions: Nonalcoholic Steatohepatitis | Phase 3 | Status: TERMINATED | Results posted: 2020-06-29